Home・Elenco Azioni・Zealand Pharma A-S

Zealand Pharma A-S

Chiusa

320.2 0.1

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

308

Massimo

324.2

Metriche Chiave
By Trading Economics
Entrata	4.3B 3.9B
Vendite	4.5B 4.5B
P/E Media del settore	8.036 57.371
EPS	55.34
Margine di Profitto	87.219
Dipendenti	578
EBITDA	4.2B 3.9B

Raccomandazioni
By TipRanks
Raccomandazioni	Neutrale
Previsioni per 12 mesi	+25.15% upside

Dividendi
By Acuity
Utili prossimi	12 nov 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-821M 21B
Apertura precedente	320.1
Chiusura precedente	320.2

Zealand Pharma A-S Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

23 ago 2026, 23:51 UTC

Bitcoin and Ethereum rise amid broader financial trends, while concerns over U.S. national debt and rising bond yields prompt Treasury interventions ahead of key economic data releases.

23 ago 2026, 23:51 UTC

Bitcoin and Ethereum rise amid concerns over U.S. national debt and bond market pressures, while Asian stocks anticipate recovery following positive U.S. market performance.

23 ago 2026, 23:51 UTC

Bitcoin and Ethereum rise as U.S. national debt hits $40 trillion, prompting concerns over economic stability and upcoming key economic data releases.

23 ago 2026, 23:51 UTC

Cryptocurrency prices rise amid U.S. national debt concerns and bond market volatility, as investors brace for major earnings reports and geopolitical tensions.

23 ago 2026, 23:51 UTC

Australia's Construction Output Expected to Rise 0.4% Amid Cautious Investor Sentiment Ahead of August Release

23 ago 2026, 23:51 UTC

Australia's RBA Trimmed Mean CPI Release on August 26, 2026, Expected to Reveal Key Insights into Core Inflation Trends Amid Global Economic Uncertainty.

23 ago 2026, 23:51 UTC

Australia's Inflation Rate Expected to Drop Slightly to 3.2% Amid Economic Shifts and Market Volatility Concerns

23 ago 2026, 23:51 UTC

Macro News

Bitcoin is higher today, continuing its upward trend since Saturday. Positive sentiment follows Wall Street's rebound amid declining interest rates and rising gold prices.

23 ago 2026, 23:51 UTC

Japan's Industrial Production Data Release on August 30 Expected to Show Continued Growth Amid Market Concerns.

23 ago 2026, 23:51 UTC

Japan's Retail Sales YoY Data Release on August 30 Expected to Show Significant Rebound Amid Mixed Economic Sentiment and Recent Stock Market Decline.

23 ago 2026, 23:41 UTC

Canada's Monthly GDP Growth Expected Amid Trade Tensions and Inflation Concerns Ahead of August 28 Release.

23 ago 2026, 23:41 UTC

Bank of Korea's Upcoming Interest Rate Decision Sparks Optimism Amid KOSPI Rally and Global Economic Trends

23 ago 2026, 23:41 UTC

Canada's GDP Growth Rate Faces Caution Amid Escalating U.S. Trade Tensions and Tariff Concerns Ahead of August 28 Release

23 ago 2026, 23:41 UTC

Canada's Q2 2026 GDP Growth Rate Release Amidst U.S. Trade Tensions and Infrastructure Boosts Scheduled for August 28, Heightening Market Scrutiny.

23 ago 2026, 23:31 UTC

RBA Bulletin Release on August 27, 2026 Sparks Anticipation Amid Global Decline in Interest Rates and Market Fluctuations.

23 ago 2026, 23:21 UTC

Upcoming U.S. Retail Inventories Ex Autos Data Release on August 27, 2026, Amid Mixed Sentiment and Economic Growth Concerns

23 ago 2026, 23:21 UTC

U.S. Goods Trade Balance Expected to Hit $99 Billion Deficit Amid Rising U.S.-Canada Tariff Tensions

23 ago 2026, 23:21 UTC

U.S. Wholesale Inventories Expected to Rise 0.1% in July Amid Mixed Market Sentiment Ahead of August Release

23 ago 2026, 23:21 UTC

Canada's Current Account Deficit Expected to Reach -5.5 Billion CAD in Q2 2026 Amid Trade Tensions with U.S.

23 ago 2026, 23:21 UTC

The CAD/CHF currency pair is lower during after-market hours, reflecting a decline since Friday's close amid notable fluctuations in its one-month trading range.

23 ago 2026, 23:21 UTC

Correlated Moves

XRP is rising during Sunday’s session, supported by Bitcoin's upward movement. The asset has gained significantly since Saturday and remains above its 20-day moving average.

23 ago 2026, 23:11 UTC

EUR/NZD is trading higher in after-market hours, continuing a gradual increase since Friday's close, despite a recent trend of lower closes.

23 ago 2026, 23:11 UTC

U.S. Home Prices Expected to Rise 1.7% YoY Amid Inflation and Economic Uncertainty, According to S&P/Case-Shiller Index

23 ago 2026, 23:11 UTC

U.S. GDP Price Index QoQ 2nd Estimate Set for August 26, Forecasting a 0.063% Increase Amid Inflation Concerns and Mixed Market Sentiment

23 ago 2026, 23:11 UTC

South Africa's Trade Balance Data Release on August 28 Expected Amid Fluctuating Trends and Commodity Market Sentiment.

23 ago 2026, 23:01 UTC

Correlated Moves

Gold/Silver is trading lower, influenced by broader market sentiment and concerns over the U.S. national debt reaching $40 trillion. It remains below its 20-day moving average.

23 ago 2026, 23:01 UTC

Gold/NZD is trading higher since Friday's close, maintaining a position above its 20-day moving average amid concerns over the U.S. national debt reaching $40 trillion.

23 ago 2026, 23:01 UTC

Gold/JPY is trading higher, reflecting a broader positive performance. The asset remains significantly above its 20-day moving average, indicating strong underlying momentum.

23 ago 2026, 23:01 UTC

Gold/HKD is higher today, reflecting a strong trend above its 20-day moving average. Earlier, it reached a high of 2.16% above Friday's close.

23 ago 2026, 23:01 UTC

Gold/SGD is higher in the current session, maintaining a gain above its 20-day moving average despite a slight pullback from earlier peaks.

Confronto tra pari

Modifica del prezzo

Zealand Pharma A-S Previsione

Obiettivo di Prezzo

By TipRanks

25.15% in crescita

Previsioni per 12 mesi

Media 270.582 DKK 25.15%

Alto 270.568 DKK

Basso 270.568 DKK

Basato su 1 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Zealand Pharma A-S - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Neutrale

1 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 1 che hanno fornito valutazioni azionarie a Zealand Pharma A-S - Dist negli ultimi 3 mesi.

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Zealand Pharma A-S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.

Altri titoli del settore

NOVO.B.DK

Novo Nordisk A-S (Class B)

302.35

↑ +1.04%

GMAB.DK

Genmab A-S

2,115

↓-1.76%

Zealand Pharma A-S

Panoramica

Variazione del prezzo dell'azione

Metriche Chiave

Raccomandazioni

Dividendi

Statistiche di mercato

Zealand Pharma A-S Grafico

Notizie correlate

Confronto tra pari

Zealand Pharma A-S Previsione

Obiettivo di Prezzo

Consenso sulla valutazione

Notizie finanziarie

Chi Siamo Zealand Pharma A-S

Altri titoli del settore